Shanghai Henlius Biotech, Inc. (2696) Announces NMPA Approval for HLX15-SC IND in Multiple Myeloma

Bulletin Express

Feb 12

Shanghai Henlius Biotech, Inc. (2696) announced that its investigational new drug application for HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection – subcutaneous injection) has been approved by the National Medical Products Administration for a phase 1 clinical trial targeting multiple myeloma. According to the announcement dated 12 February 2026, HLX15-SC was developed independently by the company and represents a subcutaneous formulation of HLX15, a proposed biosimilar to daratumumab.

HLX15 is designed to bind CD38 expressed on the surface of tumor cells, inducing tumor apoptosis through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and other immune-related mechanisms. The company completed a phase 1 clinical study of the intravenous version (HLX15-IV) in healthy Chinese male subjects in June 2024, and now plans to advance HLX15-SC into clinical development. Market data from IQVIA indicates that global sales of daratumumab reached approximately US$12.88 billion in 2024.

The announcement highlights that Shanghai Henlius Biotech, Inc. cannot guarantee the successful development and commercialization of HLX15, advising shareholders and potential investors to approach the company’s shares with caution.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1142401139"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142401139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142401139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 17:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142401139","market":"us","top_or_hot":-1,"title":"Shanghai Henlius Biotech, Inc. (2696) Announces NMPA Approval for HLX15-SC IND in Multiple Myeloma","media":"Bulletin Express","content":"<p>Shanghai Henlius Biotech, Inc. (2696) announced that its investigational new drug application for HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection – subcutaneous injection) has been approved by the National Medical Products Administration for a phase 1 clinical trial targeting multiple myeloma. According to the announcement dated 12 February 2026, HLX15-SC was developed independently by the company and represents a subcutaneous formulation of HLX15, a proposed biosimilar to daratumumab.</p>\n<p>HLX15 is designed to bind CD38 expressed on the surface of tumor cells, inducing tumor apoptosis through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and other immune-related mechanisms. The company completed a phase 1 clinical study of the intravenous version (HLX15-IV) in healthy Chinese male subjects in June 2024, and now plans to advance HLX15-SC into clinical development. Market data from IQVIA indicates that global sales of daratumumab reached approximately US$12.88 billion in 2024.</p>\n<p>The announcement highlights that Shanghai Henlius Biotech, Inc. cannot guarantee the successful development and commercialization of HLX15, advising shareholders and potential investors to approach the company’s shares with caution.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Henlius Biotech, Inc. (2696) Announces NMPA Approval for HLX15-SC IND in Multiple Myeloma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Henlius Biotech, Inc. (2696) Announces NMPA Approval for HLX15-SC IND in Multiple Myeloma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-12 17:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Henlius Biotech, Inc. (2696) announced that its investigational new drug application for HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection – subcutaneous injection) has been approved by the National Medical Products Administration for a phase 1 clinical trial targeting multiple myeloma. According to the announcement dated 12 February 2026, HLX15-SC was developed independently by the company and represents a subcutaneous formulation of HLX15, a proposed biosimilar to daratumumab.</p>\n<p>HLX15 is designed to bind CD38 expressed on the surface of tumor cells, inducing tumor apoptosis through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and other immune-related mechanisms. The company completed a phase 1 clinical study of the intravenous version (HLX15-IV) in healthy Chinese male subjects in June 2024, and now plans to advance HLX15-SC into clinical development. Market data from IQVIA indicates that global sales of daratumumab reached approximately US$12.88 billion in 2024.</p>\n<p>The announcement highlights that Shanghai Henlius Biotech, Inc. cannot guarantee the successful development and commercialization of HLX15, advising shareholders and potential investors to approach the company’s shares with caution.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"","article_id":"1142401139","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142401139","pubTimestamp":1770886840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Henlius Biotech, Inc. (2696) announced that its investigational new drug application for HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection – subcutaneous injection)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖"},"translate_title":"复宏汉霖生物技术股份有限公司（2696）宣布HLX15-SC治疗多发性骨髓瘤的IND获得NMPA批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech, Inc. (2696) announced that its investigational new drug application for HLX15-SC (recombinant anti-CD38 fully human monoclonal antibody injection – subcutaneous injection) has been approved by the National Medical Products Administration for a phase 1 clinical trial targeting multiple myeloma. According to the announcement dated 12 February 2026, HLX15-SC was developed independently by the company and represents a subcutaneous formulation of HLX15, a proposed biosimilar to daratumumab.\nHLX15 is designed to bind CD38 expressed on the surface of tumor cells, inducing tumor apoptosis through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and other immune-related mechanisms. The company completed a phase 1 clinical study of the intravenous version (HLX15-IV) in healthy Chinese male subjects in June 2024, and now plans to advance HLX15-SC into clinical development. Market data from IQVIA indicates that global sales of daratumumab reached approximately US$12.88 billion in 2024.\nThe announcement highlights that Shanghai Henlius Biotech, Inc. cannot guarantee the successful development and commercialization of HLX15, advising shareholders and potential investors to approach the company’s shares with caution.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}